Clinical Trial

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
Trial Details
NCT Number NCT06774664
Lead Sponsor Sinocelltech Ltd.
Conditions IgA Nephropathy
Enrollment 99 participants
Start Date 2025-01
Primary Completion 2027-09 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2025-01-14